EGFR and Hypomagnesemia: The longer half-life and higher affinity of panitumumab for EGFR, as well as the overexpression of EGFR, are responsible for a high incidence of grade 3/4 hypomagnesemia and hypokalemia in colorectal cancer patients (99).